The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Is your brain aging faster than your chronological age? New research shows it could raise your risk of death and dementia significantly—and offers promise for early intervention.

A cardiologist spotlights cardiac amyloidosis, a protein disease often mistaken for hypertension. Learn the signs and how to get screened.

Warning signs of an unhealthy heart, though, can lurk — not so quietly — in its many complex sounds. That's why FIU researchers Joshua Hutcheson and Valentina Dargam have come up with a way to "listen ...

It’s as if sudden cardiac arrest is met with a resigned shrug: If it’s nearly impossible to predict and even harder to treat, ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Heart failure occurs when the heart muscle does not pump blood as well as it should. Heart failure symptoms can sometimes be ...

People with cardiovascular disease, diabetes or neuropathies should avoid pedicures because they might not feel a sore and ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...